China Shineway Pharmaceutical Group Limited (2877.HK)
HKD 9.43
(-1.26%)
HKD 9.43
(-1.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.39 Billion CNY | 15.51% |
| 2022 | 2.93 Billion CNY | 21.9% |
| 2021 | 2.41 Billion CNY | 21.25% |
| 2020 | 1.98 Billion CNY | 0.32% |
| 2019 | 1.98 Billion CNY | 5.62% |
| 2018 | 1.87 Billion CNY | 48.06% |
| 2017 | 1.26 Billion CNY | -1.51% |
| 2016 | 1.28 Billion CNY | -5.47% |
| 2015 | 1.36 Billion CNY | -7.92% |
| 2014 | 1.47 Billion CNY | 0.24% |
| 2013 | 1.47 Billion CNY | 5.93% |
| 2012 | 1.39 Billion CNY | 6.9% |
| 2011 | 1.3 Billion CNY | -9.26% |
| 2010 | 1.43 Billion CNY | 21.81% |
| 2009 | 1.17 Billion CNY | 28.85% |
| 2008 | 914.31 Million CNY | 23.88% |
| 2007 | 738.03 Million CNY | 24.61% |
| 2006 | 592.3 Million CNY | 6.41% |
| 2005 | 556.6 Million CNY | 23.26% |
| 2004 | 451.57 Million CNY | 56.23% |
| 2003 | 289.04 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q4 | 1.59 Billion CNY | 0.0% |
| 2023 Q2 | 1.8 Billion CNY | 0.0% |
| 2023 FY | 3.39 Billion CNY | 15.51% |
| 2022 Q4 | 1.61 Billion CNY | 0.0% |
| 2022 Q2 | 1.32 Billion CNY | 0.0% |
| 2022 FY | 2.93 Billion CNY | 21.9% |
| 2021 Q4 | 1.26 Billion CNY | 0.0% |
| 2021 FY | 2.41 Billion CNY | 21.25% |
| 2021 Q2 | 1.14 Billion CNY | 0.0% |
| 2020 FY | 1.98 Billion CNY | 0.32% |
| 2020 Q2 | 876.36 Million CNY | 0.0% |
| 2020 Q4 | 1.11 Billion CNY | 0.0% |
| 2019 Q2 | 975.28 Million CNY | 0.0% |
| 2019 Q4 | 1 Billion CNY | 0.0% |
| 2019 FY | 1.98 Billion CNY | 5.62% |
| 2018 FY | 1.87 Billion CNY | 48.06% |
| 2018 Q4 | 946.77 Million CNY | 0.0% |
| 2018 Q2 | 929.27 Million CNY | 0.0% |
| 2017 Q4 | 763.41 Million CNY | 0.0% |
| 2017 FY | 1.26 Billion CNY | -1.51% |
| 2017 Q2 | 503.67 Million CNY | 0.0% |
| 2016 Q2 | 595.62 Million CNY | 0.0% |
| 2016 Q4 | 690.87 Million CNY | 0.0% |
| 2016 FY | 1.28 Billion CNY | -5.47% |
| 2015 FY | 1.36 Billion CNY | -7.92% |
| 2015 Q2 | 729.69 Million CNY | 0.0% |
| 2015 Q4 | 631.22 Million CNY | 0.0% |
| 2014 Q4 | 753.68 Million CNY | 0.0% |
| 2014 Q2 | 724.31 Million CNY | 0.0% |
| 2014 FY | 1.47 Billion CNY | 0.24% |
| 2013 Q4 | 767.79 Million CNY | 0.0% |
| 2013 Q2 | 706.62 Million CNY | 0.0% |
| 2013 FY | 1.47 Billion CNY | 5.93% |
| 2012 Q4 | 368.6 Million CNY | 5.93% |
| 2012 Q3 | 347.98 Million CNY | 0.0% |
| 2012 Q2 | 347.98 Million CNY | 0.0% |
| 2012 Q1 | 347.98 Million CNY | 0.0% |
| 2012 FY | 1.39 Billion CNY | 6.9% |
| 2011 Q1 | 325.52 Million CNY | 0.0% |
| 2011 Q2 | 325.52 Million CNY | 0.0% |
| 2011 Q3 | 325.52 Million CNY | 0.0% |
| 2011 Q4 | 347.98 Million CNY | 6.9% |
| 2011 FY | 1.3 Billion CNY | -9.26% |
| 2010 Q4 | 325.52 Million CNY | -9.26% |
| 2010 Q1 | 358.75 Million CNY | 0.0% |
| 2010 FY | 1.43 Billion CNY | 21.81% |
| 2010 Q3 | 358.75 Million CNY | 0.0% |
| 2010 Q2 | 358.75 Million CNY | 0.0% |
| 2009 Q3 | 294.52 Million CNY | 0.0% |
| 2009 FY | 1.17 Billion CNY | 28.85% |
| 2009 Q1 | 294.52 Million CNY | 0.0% |
| 2009 Q4 | 358.75 Million CNY | 21.81% |
| 2009 Q2 | 294.52 Million CNY | 0.0% |
| 2008 Q4 | 294.52 Million CNY | 28.85% |
| 2008 FY | 914.31 Million CNY | 23.88% |
| 2008 Q1 | 228.57 Million CNY | 0.0% |
| 2008 Q2 | 228.57 Million CNY | 0.0% |
| 2008 Q3 | 228.57 Million CNY | 0.0% |
| 2007 Q1 | 184.5 Million CNY | 0.0% |
| 2007 FY | 738.03 Million CNY | 24.61% |
| 2007 Q4 | 228.57 Million CNY | 23.88% |
| 2007 Q3 | 184.5 Million CNY | 0.0% |
| 2007 Q2 | 184.5 Million CNY | 0.0% |
| 2006 Q1 | 148.07 Million CNY | 0.0% |
| 2006 FY | 592.3 Million CNY | 6.41% |
| 2006 Q2 | 148.07 Million CNY | 0.0% |
| 2006 Q3 | 148.07 Million CNY | 0.0% |
| 2006 Q4 | 184.5 Million CNY | 24.61% |
| 2005 Q3 | 139.15 Million CNY | 0.0% |
| 2005 Q2 | 139.15 Million CNY | 0.0% |
| 2005 FY | 556.6 Million CNY | 23.26% |
| 2005 Q4 | 148.07 Million CNY | 6.41% |
| 2005 Q1 | 139.15 Million CNY | 0.0% |
| 2004 Q4 | 139.15 Million CNY | 23.26% |
| 2004 Q1 | 112.89 Million CNY | 0.0% |
| 2004 Q2 | 112.89 Million CNY | 0.0% |
| 2004 Q3 | 112.89 Million CNY | 0.0% |
| 2004 FY | 451.57 Million CNY | 56.23% |
| 2003 FY | 289.04 Million CNY | 0.0% |
| 2003 Q1 | 72.26 Million CNY | 0.0% |
| 2003 Q4 | 112.89 Million CNY | 56.23% |
| 2003 Q3 | 72.26 Million CNY | 0.0% |
| 2003 Q2 | 72.26 Million CNY | 0.0% |
| 2002 Q4 | 72.26 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | -1927.114% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 47.975% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | -11693.735% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | -759.678% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 9633.239% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | -515.645% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | -120.499% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | -620.173% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -1466.789% |
| SSY Group Limited | 3.48 Billion HKD | 2.724% |
| JBM (Healthcare) Limited | 319.41 Million HKD | -962.601% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | -447.019% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 92.173% |